CCM® Overview - Patient Education

September 1, 2020

This animation provides discusses heart failure symptoms and treatment options.  CCM therapy is introduced including the indications for use, recommendations for patient selection, and a brief description of how cardiac contractility works in the heart.  The procedure is reviewed as well as clinical trial results.

  • October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Login to view comments. Click here to Login